Published in Clin Cancer Res on March 12, 2012
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res (2013) 1.81
Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med (2013) 1.24
Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis (2014) 1.22
The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget (2014) 1.12
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst (2014) 1.09
Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets. Cancer Discov (2013) 1.01
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Mol Cancer Ther (2014) 0.97
Inactivation of a Gα(s)-PKA tumour suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. Nat Cell Biol (2015) 0.96
Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition. Neoplasia (2013) 0.95
The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer (2015) 0.93
LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene (2014) 0.93
SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/mTORC1 axis. FASEB J (2014) 0.92
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer (2013) 0.88
The role of MALAT1 correlates with HPV in cervical cancer. Oncol Lett (2014) 0.88
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer. ISRN Otolaryngol (2012) 0.85
Upregulation of URI/RMP gene expression in cervical cancer by high-throughput tissue microarray analysis. Int J Clin Exp Pathol (2013) 0.82
DNA methylation of PAX1 as a biomarker for oral squamous cell carcinoma. Clin Oral Investig (2013) 0.82
Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling. Oral Oncol (2013) 0.81
Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget (2016) 0.80
Metabolic reprogramming: a hallmark of viral oncogenesis. Oncogene (2015) 0.79
Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. Cancer Prev Res (Phila) (2015) 0.79
mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC. Oncotarget (2016) 0.78
Keratoacanthoma of the Lip: Activation of the mTOR Pathway, Tumor Suppressor Proteins, and Tumor Senescence. Medicine (Baltimore) (2015) 0.77
Activation of Akt at T308 and S473 in alcohol, tobacco and HPV-induced HNSCC: is there evidence to support a prognostic or diagnostic role? Exp Hematol Oncol (2014) 0.77
Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target. Tumour Biol (2016) 0.76
Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway. Oncotarget (2016) 0.76
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget (2016) 0.76
Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. Oncol Lett (2016) 0.75
ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy. Oncotarget (2016) 0.75
mTOR downstream effectors, 4EBP1 and eIF4E, are overexpressed and associated with HPV status in precancerous lesions and carcinomas of the uterine cervix. Oncol Lett (2016) 0.75
Induction of dormancy in hypoxic human papillomavirus-positive cancer cells. Proc Natl Acad Sci U S A (2017) 0.75
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. J Transl Med (2015) 0.75
GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway. Oncotarget (2017) 0.75
mTOR co-targeting strategies for head and neck cancer therapy. Cancer Metastasis Rev (2017) 0.75
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 16.54
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol (1995) 10.07
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97
HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (1997) 6.53
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00
MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J (2003) 3.77
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 3.70
p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol (2010) 3.37
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol (2004) 2.34
Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol (2007) 2.27
A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer (2003) 2.24
Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res (2007) 2.21
Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol (2008) 2.21
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res (2005) 2.07
Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol (2009) 1.70
Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck (2007) 1.67
Causes of oral cancer--an appraisal of controversies. Br Dent J (2009) 1.65
Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A (2011) 1.53
Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem (2004) 1.53
The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol (2010) 1.49
Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol (2011) 1.34
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol (2008) 1.30
p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am J Surg Pathol (2007) 1.20
Papillomavirus DNA in human tongue carcinomas. Int J Cancer (1985) 1.16
Snail up-regulates proinflammatory mediators and inhibits differentiation in oral keratinocytes. Cancer Res (2008) 1.14
Global gene expression profiles of human head and neck squamous carcinoma cell lines. Int J Cancer (2004) 1.13
Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther (2009) 1.10
Rac1 is required for epithelial stem cell function during dermal and oral mucosal wound healing but not for tissue homeostasis in mice. PLoS One (2010) 1.03
Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol (2008) 1.02
A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res (2008) 0.97
Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas. Virchows Arch (2010) 0.92
Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck (2010) 0.86
Advances in cervical cancer treatment. Gynecol Oncol (2011) 0.82
Detection of human papillomavirus DNA in oral mucosal lesions using in situ DNA-hybridization applied on paraffin sections. Oral Surg Oral Med Oral Pathol (1986) 0.81
G-protein-coupled receptors and cancer. Nat Rev Cancer (2007) 6.80
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science (2005) 5.68
Augmented Wnt signaling in a mammalian model of accelerated aging. Science (2007) 5.62
VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol (2006) 5.00
G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat Med (2007) 4.26
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 3.50
Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell (2003) 3.42
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res (2004) 2.95
Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila) (2009) 2.91
Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell (2010) 2.86
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell (2009) 2.74
Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells (2005) 2.52
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano (2009) 2.39
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res (2007) 2.21
Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol (2008) 2.21
Carbon nanotube amplification strategies for highly sensitive immunodetection of cancer biomarkers. J Am Chem Soc (2006) 2.19
Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell (2008) 2.13
An essential role for Rac1 in endothelial cell function and vascular development. FASEB J (2008) 2.09
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res (2005) 2.07
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer (2013) 2.05
Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res (2004) 2.05
Binding-induced folding of a natively unstructured transcription factor. PLoS Comput Biol (2008) 2.04
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell (2012) 1.99
CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem (2008) 1.93
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev (2005) 1.92
Tissues from population-based cancer registries: a novel approach to increasing research potential. Hum Pathol (2005) 1.92
Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proc Natl Acad Sci U S A (2011) 1.85
The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell (2004) 1.85
Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res (2004) 1.83
Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res (2008) 1.83
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3. Nat Immunol (2010) 1.77
Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Proc Natl Acad Sci U S A (2006) 1.76
Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. Analyst (2010) 1.73
Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res (2004) 1.70
Plexin B regulates Rho through the guanine nucleotide exchange factors leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF. J Biol Chem (2002) 1.69
Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification. ACS Nano (2009) 1.68
P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J Biol Chem (2007) 1.67
The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell (2006) 1.63
mom identifies a receptor for the Drosophila JAK/STAT signal transduction pathway and encodes a protein distantly related to the mammalian cytokine receptor family. Genes Dev (2002) 1.63
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60
Rac1 function is required for Src-induced transformation. Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. J Biol Chem (2003) 1.60
The Galpha13-Rho signaling axis is required for SDF-1-induced migration through CXCR4. J Biol Chem (2006) 1.58
The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. Proc Natl Acad Sci U S A (2002) 1.58
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics (2009) 1.57
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55
Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res (2011) 1.54
Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res (2008) 1.54
Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential. Oncogene (2004) 1.52
Regulation of G protein-linked guanine nucleotide exchange factors for Rho, PDZ-RhoGEF, and LARG by tyrosine phosphorylation: evidence of a role for focal adhesion kinase. J Biol Chem (2002) 1.52
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A (2004) 1.52
MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J Biol Chem (2007) 1.51
Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res (2004) 1.50
Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. Mol Cell Biol (2010) 1.50
Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene (2002) 1.49
Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene (2002) 1.46
A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal (2011) 1.45
Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification. Anal Chem (2010) 1.42
Viral hijacking of G-protein-coupled-receptor signalling networks. Nat Rev Mol Cell Biol (2004) 1.42
Semaphorin 4D/plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway. Mol Cell Biol (2005) 1.42
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem (2007) 1.41
A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors. Mol Cell (2012) 1.40
Robo4 signaling in endothelial cells implies attraction guidance mechanisms. J Biol Chem (2006) 1.38
Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol Cell Biol (2003) 1.38
Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res (2009) 1.37
Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem (2005) 1.36
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36
Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum. Biosens Bioelectron (2011) 1.35
Potent activation of RhoA by Galpha q and Gq-coupled receptors. J Biol Chem (2002) 1.35
Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. Oncogene (2003) 1.35
Ultrasensitive detection of cancer biomarkers in the clinic by use of a nanostructured microfluidic array. Anal Chem (2012) 1.34
p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res (2012) 1.32
Single-wall carbon nanotube forest arrays for immunoelectrochemical measurement of four protein biomarkers for prostate cancer. Anal Chem (2009) 1.31
Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res (2012) 1.30
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest (2014) 1.29
Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions. Clin Cancer Res (2008) 1.26